SCHEMBL6286924

SCHEMBL6286924

COc1ccc(-c2cc3cnncc3[nH]2)cc1N

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 2/20 0.44
ALDH1A1 P00352 4/20 0.40
KIT P10721 1/20 0.40
CYP3A4 P08684 1/20 0.40
AURKA O14965 1/20 0.40
FYN P06241 1/20 0.40
CCNA2 P20248 1/20 0.40
CDK2 P24941 1/20 0.40
TTK P33981 1/20 0.40
MAPT P10636 2/20 0.39
KDM4E B2RXH2 1/20 0.39
NPC1 O15118 1/20 0.39
CASP3 P42574 1/20 0.39
RAB9A P51151 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
MEN1 O00255 1/20 0.39
THRB P10828 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6282533 0.85 KDM4E (0.47) ALDH1A1CYP3A4AURKATTKMAPT
SCHEMBL6286157 0.85 KDM4E (0.44) CYP1A1ALDH1A1CYP3A4AURKATTK
SCHEMBL6503284 0.81 RAB9A (0.61) CYP1A1ALDH1A1CCNA2CDK2MAPT
SCHEMBL6286918 0.80 PARP1 (0.47) AURKAFYNCCNA2CDK2TTK
Hydrochloric Acid SCHEMBL6502726 0.80 RAB9A (0.60) CYP1A1ALDH1A1CCNA2CDK2MAPT
SCHEMBL7089024 0.79 CYP1A1 (0.43) CYP1A1ALDH1A1CYP3A4MAPTKDM4E
SCHEMBL6494925 0.79 CYP1A1 (0.43) CYP1A1ALDH1A1CYP3A4MAPTKDM4E
SCHEMBL6493592 0.79 CYP1A1 (0.51) CYP1A1ALDH1A1CYP3A4MAPTKDM4E
Hydrochloric Acid SCHEMBL6496441 0.78 CYP1A1 (0.50) CYP1A1ALDH1A1CYP3A4MAPTKDM4E
SCHEMBL6281866 0.78 ALDH1A1 (0.54) ALDH1A1CYP3A4MAPTKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040014759-A1 6,5-Fused bicyclic heterocycles PICARD JOSEPH ARMAND (US) 2004-01-22 US claimed
EP-1294718-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY LLC (US) 2003-03-26 EP claimed
WO-2001096336-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY (US) 2001-12-20 WO claimed
US-6943174-B2 6,5-Fused bicyclic heterocycles WARNER-LAMBERT COMPANY (US) 2005-09-13 US disclosed
EP-1294718-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY LLC (US) 2003-03-26 EP disclosed
WO-2001096336-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014759-A1 6,5-Fused bicyclic heterocycles ALOX15, ALOX5, ALOX15B CYP1A1 45/4885ALDH1A1 522/4885KIT 2059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.